Carflizomib is Extraordinarily Active in Myeloma  Mainstay drug for physicians and patients

Carflizomib is Extraordinarily Active in Myeloma Mainstay drug for physicians and patients

ASHReport

2 years
260 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.
Up Next Autoplay